Form 4 for NPCE NeuroPace Inc
Accepted 2023-02-22 00:00:00 ET · period of report 2023-02-21 · accession 0001209191-23-011945 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-22 | 2023-02-21 | NPCE | Favet Michael | CEO, Dir | A - Grant | $0.00 | +225.0K | 407.1K | +124% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-21 | A | A | 225,000 | $0.00 | 407,080 | D | — | — | (F1) Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 21, 2024 and the remaining RSUs vest in eight (8) equal quarterly installments thereafter. |